Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on July 24, 2007. The filing addresses Item 5.02 regarding the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
The Board of Directors approved increases to the base salaries of four executive officers, effective retroactively to January 1, 2007. Additionally, a future salary increase and a potential bonus for the Chief Financial Officer are contingent upon the closing of a capital offering with gross proceeds of at least $80,000,000.
- David Aviezer, Ph.D. (CEO): Monthly salary increased to NIS 115,000 (approx. $26,590).
- Yoseph Shaaltiel, Ph.D. (EVP, R&D): Monthly salary increased to NIS 55,000 (approx. $12,717).
- Einat Brill Almon, Ph.D. (VP, Product Development): Monthly salary increased to NIS 49,500 (approx. $11,445).
- Yossi Maimon, CPA (CFO): Monthly salary increased to NIS 47,500 (approx. $10,983), with a scheduled increase to NIS 49,500 (approx. $11,445) effective August 1, 2007.
Guidance, Outlook, and Contingencies
The Board established a "significant event" trigger tied to a capital raise of at least $80,000,000. Upon the closing of such an offering:
- Mr. Maimon will be entitled to a bonus amount to be determined by the Company.
- Monthly base salaries for all four officers will increase further to the following levels:
- CEO: NIS 150,000 (approx. $34,594)
- EVP, R&D: NIS 60,500 (approx. $13,953)
- VP, Product Development: NIS 54,000 (approx. $12,479)
- CFO: NIS 54,000 (approx. $12,479)
Investor Verification Checklist
- Verify the current cash position of the company to assess the immediate impact of the retroactive salary increases.
- Monitor progress on capital raising efforts to determine if the $80,000,000 threshold for the "significant event" is met.
- Review the specific terms of the Employment Agreement dated October 15, 2006, regarding the bonus calculation for the CFO.
- Confirm the exchange rate used for the NIS to USD conversions provided in the filing.